Skip to main content
Top
Published in: Diabetologia 9/2014

01-09-2014 | Commentary

Evidence-based estimation of insulin resistance

Author: John R. Petrie

Published in: Diabetologia | Issue 9/2014

Login to get access

Abstract

Insulin resistance is a complex phenotype. Surrogate markers based on peripheral glucose and insulin (and in some cases NEFA) concentrations can provide, at best, moderate approximations to direct physiological measurements (Pearson r values 0.6–0.7). Where the focus is solely on insulin resistance, the evidence reviewed in the paper by Otten et al in this issue (DOI: 10.​1007/​s00125-014-3285-x) suggests that surrogate markers based on fasting samples alone are as valid as those that require multiple samples and an oral glucose load. This provides an evidence base for simplifying the design of some clinical studies.
Literature
1.
go back to reference Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs – insights from the rosiglitazone experience. N Engl J Med 369:1285–1287PubMedCrossRef Hiatt WR, Kaul S, Smith RJ (2013) The cardiovascular safety of diabetes drugs – insights from the rosiglitazone experience. N Engl J Med 369:1285–1287PubMedCrossRef
2.
4.
go back to reference DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214–E223PubMed
5.
go back to reference Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC study (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47:566–570 Hills SA, Balkau B, Coppack SW et al (2004) The EGIR-RISC study (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 47:566–570
6.
go back to reference Wagenknecht LE, Mayer EJ, Rewers M et al (1995) The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 5:464–472PubMedCrossRef Wagenknecht LE, Mayer EJ, Rewers M et al (1995) The insulin resistance atherosclerosis study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 5:464–472PubMedCrossRef
7.
go back to reference Kozakova M, Natali A, Dekker J et al (2013) Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. Arterioscler Thromb Vasc Biol 33:1409–1417PubMedCrossRef Kozakova M, Natali A, Dekker J et al (2013) Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. Arterioscler Thromb Vasc Biol 33:1409–1417PubMedCrossRef
8.
go back to reference Petrie JR, Malik MO, Balkau B et al (2013) Euglycemic clamp insulin sensitivity and longitudinal systolic blood pressure: role of sex. Hypertension 62:404–409PubMedCrossRef Petrie JR, Malik MO, Balkau B et al (2013) Euglycemic clamp insulin sensitivity and longitudinal systolic blood pressure: role of sex. Hypertension 62:404–409PubMedCrossRef
Metadata
Title
Evidence-based estimation of insulin resistance
Author
John R. Petrie
Publication date
01-09-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 9/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3322-9

Other articles of this Issue 9/2014

Diabetologia 9/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.